E. Mortensen (Simsbury, United States), L. Fregonese (London, United Kingdom)
COVID-19: Vaccinated versus unvaccinated or not fully vaccinated patients
A. Digalaki (Athens, Greece), G. Hillas (Athens, Greece), S. Koukidou (Athens, Greece), A. Sakellaropoulou (Athens, Greece), C. Kosti (Athens, Greece), S. Chrysikos (Athens, Greece), K. Dimakou (Athens, Greece)
|   |
Clinical characteristics and respiratory care of hospitalized patients according to vaccination status of COVID 19
M. Suarez Ortiz (Madrid, Spain), J. Teran Tinedo (Madrid, Spain), M. Lorente Gonzalez (Madrid, Spain), D. Laorden Escudero (Madrid, Spain), A. Zevallos Villegas (Madrid, Spain), E. Cano Sanz (Madrid, Spain), M. Ortega Fraile (Madrid, Spain), J. Hernandez Nuñez (Madrid, Spain), M. Saiz Lou (Madrid, Spain), P. Landete Rodriguez (Madrid, Spain)
| |
Determinants of antibody responses to primary courses and booster doses of SARS-CoV-2 vaccines in 9,101 UK adults
D. Jolliffe (London, United Kingdom), S. Faustini (Birmingham, United Kingdom), H. Holt (London, United Kingdom), M. Talaei (London, United Kingdom), G. Vivaldi (London, United Kingdom), A. Richter (Birmingham, United Kingdom), S. Shaheen (London, United Kingdom), A. Martineau (London, United Kingdom)
| |
Effectiveness of the pneumococcal polysaccharide and conjugated vaccines in elderly and high-risk populations in preventing invasive pneumococcal disease: A systematic search and review of the literature
M. Sikjær (Vejle, Denmark), M. Wik (Vejle, Denmark), S. Stensholt (Vejle, Denmark), O. Hilberg (Vejle, Denmark), A. Løkke (Vejle, Denmark)
| |
Vaccine efficacy in severe COVID-19 patients before and after the Delta variant endemic
M. Mineshita (Kawasaki (Kanagawa), Japan), K. Nishiyama (Kawasaki (Kanagawa), Japan), S. Tanaka (Kawasaki (Kanagawa), Japan), Y. Shinozaki (Kawasaki (Kanagawa), Japan), J. Shibuya (Kawasaki (Kanagawa), Japan), H. Tsuruoka (Kawasaki (Kanagawa), Japan), K. Kinoshita (Kawasaki (Kanagawa), Japan), S. Matsuzawa (Kawasaki (Kanagawa), Japan), S. Azagami (Kawasaki (Kanagawa), Japan), H. Muraoka (Kawasaki (Kanagawa), Japan), A. Ishida (Kawasaki (Kanagawa), Japan), K. Morikawa (Kawasaki (Kanagawa), Japan), H. Kida (Kawasaki (Kanagawa), Japan), H. Handa (Kawasaki (Kanagawa), Japan), H. Nishine (Kawasaki (Kanagawa), Japan), T. Inoue (Kawasaki (Kanagawa), Japan)
| |
Immunogenicity and clinical effectiveness of the SINOVAC vaccine in patients older than 70 years
A. Giraldo Montoya (Pereira, Colombia), G. García Castro (Pereira, Colombia), A. Giraldo Montoya (Pereira, Colombia)
| |
Long-term efficacy of an inactivated whole particle H5N1 virus against H5N1 highly pathogenic avian influenza virus challenge in cynomolgus monkeys
M. Nakayama (Otsu, Japan), H. Ishigaki (Otsu, Japan), N. Thanh Cong (Otsu, Japan), S. Suzuki (Otsu, Japan), H. Ishida (Otsu, Japan), N. Kitagawa (Otsu, Japan), K. Ogasawara (Otsu, Japan), Y. Itoh (Otsu, Japan)
| |
Evaluating pneumococcal vaccine’s effectiveness against pneumonia among adults over 50 years in Catalonia, 2017-2018.
c. de diego cabanes (Tarragona, Spain), A. Vila-Corcoles (Tarragona, Spain), E. Satué-Gracia (Tarragona, Spain), O. Ochoa-Gondar (Tarragona, Spain), A. Vila-Rovira (Barcelona, Spain), M. Forcadell-Peris (Tarragona, Spain)
| |
Messenger RNA COVID-19 vaccine: What side effects?
W. Ayed (Tunis, Tunisia), D. Brahim (Tunis, Tunisia), N. Belloumi (Tunis, Tunisia), W. Haouari (Tunis, Tunisia), N. Mechergui (Tunis, Tunisia), G. Bahri (Tunis, Tunisia), I. Bachouch (Tunis, Tunisia), N. Ladhari (Tunis, Tunisia), I. Youssef (Tunis, Tunisia)
| |
Experimental Human Pneumococcal Challenge can be performed safely and is associated with low rates of rescue antibiotic use in healthy adults
R. Robinson (Liverpool, United Kingdom), C. Myerscough (Liverpool, United Kingdom), H. Hill (Liverpool, United Kingdom), W. Shephard (Liverpool, United Kingdom), K. Liatsikos (Liverpool, United Kingdom), S. Latham (Liverpool, United Kingdom), F. Fyles (Liverpool, United Kingdom), K. Doherty (Liverpool, United Kingdom), F. Shiham (Liverpool, United Kingdom), D. Mclenghan (Liverpool, United Kingdom), A. Hyder-Wright (Liverpool, United Kingdom), E. Mitsi (Liverpool, United Kingdom), H. Burhan (Liverpool, United Kingdom), B. Morton (Liverpool, United Kingdom), S. Gordon (Blantyre, Malawi), A. Collins (Liverpool, United Kingdom), D. Ferreira (Liverpool, United Kingdom)
| |
Reasons for reluctance to covid-19 vaccination among health care workers
S. Chemingui (tunis, Tunisia), N. Mechergui (tunis, Tunisia), N. Belloumi (tunis, Tunisia), M. Mersni (TUNIS, Tunisia), I. Bachouch (tunis, Tunisia), D. Brahim (tunis, Tunisia), H. Belhouen (tunis, Tunisia), N. Ladhari (TUNIS, Tunisia), I. Youssef (tunis, Tunisia)
| |
Efficacy of corona virus disease 2019 vaccines on oxygen demand, intensive care unit administration and mortality: a single centre retrospective study
H. Yesildagli (Nicosia, Cyprus), B. Cihangir (Nicosia, Cyprus), B. Kamiloglu (Nicosia, Cyprus)
| |
Attitudes of the health personnel of the Hassan II hospital in Agadir towards the 3rd dose of the vaccine anti-covid-19
A. Imzil (Agadir, Morocco), H. Moubachir (Agadir, Morocco), H. Serhane (Agadir, Morocco)
| |
Evaluation of lung immune response to the BNT162b2 COVID-19 vaccine
D. Padawer (Jerusalem, Israel), M. Stolovich-Rain (Jerusalem, Israel), M. Billan (Jerusalem, Israel), N. Berkman (Jerusalem, Israel), A. Rouvinski (Jerusalem, Israel)
| |
Clinical outcomes in vaccinated and unvaccinated patients with COVID-19: a population- based analysis
O. Papaioannou (Patras, Greece), T. Karampitsakos (Patras, Greece), P. Tsiri (Patras, Greece), V. Sotiropoulou (Patras, Greece), E. Koulousousa (Patras, Greece), P. Tasiopoulos (Patras, Greece), C. Chourpiliadi (Patras, Greece), A. Matsioulas (Patras, Greece), M. Katsaras (Patras, Greece), E. Zarkadi (Patras, Greece), G. Tsirikos (Patras, Greece), E. Theochari (Patras, Greece), E. Malakounidou (Patras, Greece), V. Georgiopoulou (Patras, Greece), D. Papalexatos (Patras, Greece), F. Sampsonas (Patras, Greece), A. Tzouvelekis (Patras, Greece)
| |
Personalized predictions of adverse side effects to the COVID-19 vaccines
E. Jamshidi (Tehran, Islamic Republic of Iran), A. Asgari (Tehran, Islamic Republic of Iran), N. Mansouri (Lausanne, Switzerland)
| |
Factors affecting vaccine acceptance and uptake among COPD patients.
M. Fekete (Budapest, Hungary), Z. Szarvas (Budapest, Hungary), V. Fazekas-Pongor (Budapest, Hungary), A. Lehoczki (Budapest, Hungary), J. Varga (Budapest, Hungary)
| |
Breakthrough infections with SARS-CoV-2 B.1.617.2 variant B.1.617.2 and humoral reponse in vaccinated maintenance hemodialysis patients
O. Wand (Ashkelon, Israel), N. Nacasch (Kfar-Saba, Israel), S. Benchetrit (Kfar-Saba, Israel), K. Cohen-Hagai (Kfar-Saba, Israel)
| |
Assessment of Predictors for SARS-CoV-2 Antibodies Decline Rate in Health Care Workers after BNT162b2 Vaccination-Results from a Serological Survey
A. Bar-Shai (Tel-Aviv, Israel), N. Zacks (Beer-Sheva, Israel), C. Levi (Ashkelon, Israel), A. Breslavsky (Ashkelon, Israel), S. Maayan (Ashkelon, Israel), E. Tsiba (Ashkelon, Israel), S. Fytlovich (Ashkelon, Israel), O. Wand (Ashkelon, Israel), M. Shaffer (Ashkelon, Israel), Y. Sherer (Ashkelon, Israel), G. Givaty (Ashkelon, Israel), A. Tzurel Ferber (Ashkelon, Israel), M. Tal (Beer-Sheva, Israel), N. Bilenko (Beer-Sheva, Israel)
| |
The intensive care unit admissions and mortality rates of the Covid-19 patients whose chest imaging findings were progressed during hospitalization: Is there any difference between vaccinated or unvaccinated patients?
E. Kamiloglu (nicosia, Cyprus), B. Cihangir (nicosia, Cyprus)
| |